[태그:] 영문
-
Episode 7: Prader-Willi and Angelman Syndromes — Beyond the Variant
📌 Series Introduction This series is authored by clinical genetics experts at 3billion. In an era where AI-driven variant prioritization has become commonplace, we focus on what interpreters truly need to understand and how they should exercise clinical judgment after automated tools have done their part. Each episode centers on a specific disease group, exploring…
-
Family Insight Test Webinar: Clarity for Your Family’s Future
Join our webinar to discover how 3billion’s Family Insight Test provides the answers you’ve been searching for. Key Highlights of the Session Ready to Attend? Simply sign up via the button below. We’ll send the YouTube webinar link directly to your inbox.
-
3billion Reports 68% YoY Revenue Growth in Q1: Strengthening Growth Foundation Through New Test Launch
SEOUL, South Korea — 3billion (CEO Changwon Kum), an AI-powered rare disease diagnostics company, announced on the 12th that its consolidated revenue for the first quarter of this year reached KRW 3.36 billion, marking a 68% increase compared to the same period last year. The company reported an operating loss of KRW 1.66 billion and…
-
Treacher Collins Syndrome: Identifying Genetic Causes via Advanced Sequencing
📍Key Takeaways 1. Resolving Genetic Heterogeneity and Inheritance Uncertainty TCS is caused by mutations in TCOF1, POLR1B, POLR1C, or POLR1D. Genetic testing is essential to differentiate between autosomal dominant and recessive inheritance, resolving uncertainties that clinical observation alone cannot address. 2. Enhancing Accuracy in Recurrence Risk Counseling Misclassifying the inheritance pattern based solely on phenotype…
-
3billion Secures 300 Billion KRW in Post-IPO Funding to Accelerate Global AI Genetic Diagnostics Leadership
■ Financial Stability Secured via CPS and CB Mix; Focus on U.S. Insurance Market Entry and Expansion of Diagnostic Portfolio ■ 0% Surface and Maturity Interest Rates: Major Institutional Investors Including Kiwoom PE and GVA Asset Management Participate ■ Targeting 30 Million Rare Disease Patients in the U.S. and Diversifying Portfolio into Non-Symptomatic Screening Markets…
-
3billion Visits Embassy of Argentina in Seoul to Discuss Expanding Precision Medicine Network in South America
SEOUL, South Korea – 3billion announced that it recently conducted an official visit to the Embassy of Argentina in Seoul to discuss strategic cooperation with Ambassador Darío Celaya and key embassy officials. The meeting was held following a formal invitation from Ambassador Darío César Celaya Alvarez, with María Virginia Yapur (Head of the Commercial Section)…
-
3billion Presents GEBRA™ SaaS Implementation and Global Expansion at AWS HealthTech Seminar
3billion Shares GEBRA™ SaaS Implementation and Global Expansion Story at ‘HealthTech Global Expansion Seminar 2026’ On April 28, 3billion participated as a speaker at the ‘HealthTech Global Expansion Seminar 2026’ hosted by Amazon Web Services (AWS), where the company shared its experience in building the SaaS platform for GEBRA—its AI-powered genetic variant interpretation software—and its…
-
Delegation from Puerto Rico’s DEDC Meets with 3billion
On April 22, a high-level delegation from Puerto Rico’s Department of Economic Development and Commerce (DEDC) and Invest Puerto Rico (Invest PR) visited the 3billion. The meeting was organized to explore strategic cooperation for 3billion’s expansion into the United States and Latin American (LATAM) markets, particularly as Puerto Rico is recognized as one of the…
-
![Differences Between Raw Data and Clinical Reports | NGS Data Analysis Workflow [Part 2]](http://d15q5w6b9vqac5.cloudfront.net/wp-content/uploads/2026/05/04180709/7.png)
Differences Between Raw Data and Clinical Reports | NGS Data Analysis Workflow [Part 2]
📍Key Takeaways Missed Part 1? Read it here! [Go to Article] Why do raw data and clinical reports differ? “Why wasn’t this variant reported?” After WES/WGS testing, many users review their VCF files (annotated data).And very naturally, they ask questions like: To answer these questions, we need to clarify one key point first. Raw data…